ストックスクリーナーアプリを入手
0.7447
0.72%
-0.0054
アフターアワーズ：
.78
0.0353
+4.74%
前日終値:
$0.7501
開ける：
$0.722
24時間の取引高:
323.78K
Relative Volume:
1.70
時価総額：
$26.38M
収益：
$42.62M
当期純損益:
$-8.32M
株価収益率:
-1.4051
EPS:
-0.53
ネットキャッシュフロー:
$-15.77M
1週間 パフォーマンス:
-45.84%
1か月 パフォーマンス:
-13.89%
6か月 パフォーマンス:
-55.41%
1年 パフォーマンス:
+48.94%
1日の値動き範囲:
$0.7005
$0.76
1週間の範囲:
$0.68
$1.50
52週間の値動き範囲:
$0.45
$3.25
Equillium Inc Stock (EQ) Company Profile
Equillium Inc Stock (EQ) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-10-29 | 再開されました | Stifel | Buy |
| 2021-09-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-07-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-10 | 再開されました | Stifel | Buy |
| 2019-02-22 | 開始されました | SVB Leerink | Outperform |
Equillium Inc (EQ) 最新ニュース
Equillium says Ono not acquiring itolizumab, stock craters 36% - MSN
Ono says no to Equillium’s itolizumab - The Pharma Letter
Jones Trading Downgrades Equillium (EQ) - MSN
Equillium retains rights to itolizumab after Ono's option expires - Investing.com India
Equillium shares downgraded to hold from buy By Investing.com - Investing.com Canada
Equillium shares downgraded to hold from buy - Investing.com India
Equillium keeps equilibrium in GVHD after Ono no-go - BioWorld Online
Equillium says Ono not acquiring itolizumab, stock craters 36% (NASDAQ:EQ) - Seeking Alpha
Equillium Maintains Rights to Itolizumab Following Ono Partnership - StockTitan
Equillium COO Christine Zedelmayer sells $18,750 in stock - Investing.com
Equillium COO Christine Zedelmayer sells $18,750 in stock By Investing.com - Investing.com Australia
Insider Sale: Sr. Vice President and COO Christine Zedelmayer Se - GuruFocus.com
Moleculin Biotech (NASDAQ:MBRX) versus Equillium (NASDAQ:EQ) Financial Comparison - Defense World
Renaissance Technologies LLC Acquires 91,200 Shares of Equillium, Inc. (NASDAQ:EQ) - Defense World
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer - StockTitan
Equillium CFO Jason Keyes sells $8,100 in company stock By Investing.com - Investing.com South Africa
Equillium CFO Jason Keyes sells $8,100 in company stock - Investing.com India
Lacklustre Performance Is Driving Equillium, Inc.'s (NASDAQ:EQ) 28% Price Drop - Simply Wall St
Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Equillium executive sells $32,985 in stock - Investing.com India
Equillium executive sells $32,985 in stock By Investing.com - Investing.com Australia
Equillium collaborates with Vivtex for oral formulation of autoimmune therapy - Yahoo Finance
Vivtex Enters New Research Agreement with Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy - ForexTV.com
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit - StockTitan
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Wall Street analysts’ outlook for Equillium Inc (EQ) - SETE News
Equillium Inc’s Market Journey: Closing Weak at 1.07, Down -0.93 - The Dwinnex
How should investors view Equillium Inc (EQ)? - US Post News
Equillium Inc Inc. (EQ) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference - StockTitan
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26 - Business Wire
Q3 2024 Earnings Forecast for Equillium, Inc. (NASDAQ:EQ) Issued By HC Wainwright - Defense World
Equillium, Inc. (NASDAQ:EQ) Forecasted to Post FY2024 Earnings of $0.62 Per Share - Defense World
Equillium’s (EQ) Buy Rating Reiterated at HC Wainwright - Defense World
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience - Marketscreener.com
Equillium Second Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Equillium (NASDAQ:EQ) Issues Quarterly Earnings Results, Beats Estimates By $0.16 EPS - Defense World
EQEquillium, Inc. Latest Stock News & Market Updates - StockTitan
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates - MSN
Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights - StockTitan
Equillium Inc (EQ) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Equillium's itolizumab advances in phase 3 aGVHD trial - Investing.com
Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease - StockTitan
Acadian Asset Management LLC Acquires New Holdings in Equillium, Inc. (NASDAQ:EQ) - Defense World
Equillium faces delisting risk, Nasdaq warns on bid price - Investing.com India
Equillium faces delisting risk, Nasdaq warns on bid price By Investing.com - Investing.com Canada
Equillium CFO Jason Keyes sells shares worth $8,700 - Investing.com
Equillium reports $33.3 million in cash and investments By Investing.com - Investing.com
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance - StockTitan
Equillium Inc (EQ) 財務データ
収益
当期純利益
現金流量
EPS
Equillium Inc (EQ) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Zedelmayer Christine | Sr. Vice President and COO |
Oct 28 '24 |
Sale |
1.25 |
15,000 |
18,750 |
135,246 |
| Tom Penny | Principal Accounting Officer |
Oct 28 '24 |
Sale |
1.25 |
2,835 |
3,544 |
6,533 |
| Tom Penny | Principal Accounting Officer |
Oct 25 '24 |
Sale |
1.25 |
683 |
854 |
9,368 |
| Keyes Jason A | Chief Financial Officer |
Sep 26 '24 |
Sale |
0.81 |
10,000 |
8,100 |
57,720 |
| Tom Penny | Principal Accounting Officer |
Sep 16 '24 |
Sale |
0.85 |
38,806 |
32,985 |
10,051 |
| Keyes Jason A | Chief Financial Officer |
Jul 16 '24 |
Sale |
0.87 |
10,000 |
8,700 |
67,720 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):